B-Cell Maturation Antigen (BCMA)

Overview

B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.

Explore Tags

Myeloma Treatments

The following is a listing of myeloma treatments associated with this tag.

All Treatments

View all treatments in development for myeloma patients around the US.

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified GSK2857916
GSK2857916

GSK2857916 is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a new antibody targeting the B-cell maturation antigen (BCMA) protein and being tested in multiple myeloma.

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Early Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified GSK2857916
GSK2857916

GSK2857916 is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Late Relapse Multiple Myeloma

The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified Descartes-08
Descartes-08

Descartes-08 is a cell therapy wherein T-cells are modified to attack myeloma cells. To modify the cells, new instructions (called RNA) are inserted into the T-cells.

Verified GSK2857916
GSK2857916

GSK2857916 is an antibody-drug conjugate (ADC) directed against the B-cell maturation antigen (BCMA).

Verified SEA-BCMA
SEA-BCMA

SEA-BCMA is a new antibody targeting the B-cell maturation antigen (BCMA) protein and being tested in multiple myeloma.

Verified TNB-383B
TNB-383B

TNB-383B is a bi-specific antibody, meaning that it interacts with two molecules in your body. One molecule is called B-Cell Maturation Antigen (BMCA) and is found on your multiple myeloma cells. The second is called CD3 and is present on your killer T-cells.

SparkCures Verified Accurate, up-to-date information. Learn more


Myeloma Clinical Trials

The following is a listing of myeloma clinical trials associated with this tag.

All Clinical Trials

View all active clinical trials around the US.

SparkCures Verified Accurate, up-to-date information. Learn more


Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

SparkCures Verified Accurate, up-to-date information. Learn more


Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Myeloma Tags

The following is a listing of myeloma tags that are associated with this tag.

Antibody Drug Conjugate

Antibody Drug Conjugates (ADC) work by combining a chemotherapy drug with a monoclonal antibody. This allows the chemotherapy drug to target a specific cancer cell while limiting the damage to healthy cells.

Bispecific Antibody

A bispecific antibody is a drug that has been designed to simultaneously target two different proteins. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells.

Bispecific T Cell Engager (BiTE)

BiTEs are a type of immunotherapy. They consist of monoclonal antibodies that can target and bind to both myeloma cells and T Cells.

CAR T Cell

CAR T Cell therapy is a new way to treat multiple myeloma using your own immune system to target and destroy cancer cells.

Monoclonal Antibody

Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.

Resources